{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:44:39Z","timestamp":1778622279413,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3757-8","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T06:51:41Z","timestamp":1510642301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials"],"prefix":"10.1186","volume":"17","author":[{"given":"Sajesh K.","family":"Veettil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kean Ghee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siew Mooi","family":"Ching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surasak","family":"Saokaew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pochamana","family":"Phisalprapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"key":"3757_CR1","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMra1513581","volume":"374","author":"WB Strum","year":"2016","unstructured":"Strum WB. Colorectal Adenomas. N Engl J Med. 2016;374:1065\u201375.","journal-title":"N Engl J Med"},{"key":"3757_CR2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jnci\/95.10.697","volume":"95","author":"B Levin","year":"2003","unstructured":"Levin B. Potential pitfalls in the use of surrogate endpoints in colorectal adenoma chemoprevention. J Natl Cancer Inst. 2003;95:697\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"3757_CR3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1136\/gut.2003.026112","volume":"53","author":"Y Yamaji","year":"2004","unstructured":"Yamaji Y, Mitsushima T, Ikuma H, Watabe H, Okamoto M, Kawabe T, et al. Incidence and recurrence rates of colorectal adenomas estimated by annually repeated colonoscopies on asymptomatic Japanese. Gut. 2004;53:568\u201372.","journal-title":"Gut"},{"key":"3757_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000071364","volume":"37","author":"JA Baron","year":"2003","unstructured":"Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res. 2003;37:1\u201324.","journal-title":"Prog Exp Tumor Res"},{"key":"3757_CR5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-146-5-200703060-00009","volume":"146","author":"C Dub\u00e9","year":"2007","unstructured":"Dub\u00e9 C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med. 2007;146:365\u201375.","journal-title":"Ann Intern Med"},{"key":"3757_CR6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/0003-4819-146-5-200703060-00010","volume":"146","author":"A Rostom","year":"2007","unstructured":"Rostom A, Dub\u00e9 C, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med. 2007;146:376\u201389.","journal-title":"Ann Intern Med"},{"key":"3757_CR7","doi-asserted-by":"crossref","unstructured":"Asano TK, McLeod RS. Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev. 2004:CD004079.","DOI":"10.1002\/14651858.CD004079.pub2"},{"key":"3757_CR8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djn485","volume":"101","author":"BF Cole","year":"2009","unstructured":"Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101:256\u201366.","journal-title":"J Natl Cancer Inst"},{"key":"3757_CR9","first-page":"893","volume":"11","author":"F Gao","year":"2009","unstructured":"Gao F, Liao C, Liu L, Tan A, Cao Y, Mo Z. The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. Colorectal Dis Off J Assoc Coloproctology G B Irel. 2009;11:893\u2013901.","journal-title":"Colorectal Dis Off J Assoc Coloproctology G B Irel"},{"key":"3757_CR10","first-page":"1","volume":"14","author":"K Cooper","year":"2010","unstructured":"Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess Winch Engl. 2010;14:1\u2013206.","journal-title":"Health Technol Assess Winch Engl"},{"key":"3757_CR11","first-page":"2711","volume":"17","author":"T-Y Zhao","year":"2016","unstructured":"Zhao T-Y, Tu J, Wang Y, Cheng D-W, Gao X-K, Luo H, et al. The efficacy of aspirin in preventing the recurrence of colorectal adenoma: a renewed meta-analysis of randomized trials. Asian Pac. J Cancer Prev APJCP. 2016;17:2711\u20137.","journal-title":"J Cancer Prev APJCP"},{"key":"3757_CR12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa021735","volume":"348","author":"JA Baron","year":"2003","unstructured":"Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891\u20139.","journal-title":"N Engl J Med"},{"key":"3757_CR13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0016-5085(03)00887-4","volume":"125","author":"R Benamouzig","year":"2003","unstructured":"Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125:328\u201336.","journal-title":"Gastroenterology"},{"key":"3757_CR14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2007.10.014","volume":"134","author":"RFA Logan","year":"2008","unstructured":"Logan RFA, Grainge MJ, Shepherd VC, Armitage NC, Muir KR, ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008;134:29\u201338.","journal-title":"Gastroenterology"},{"key":"3757_CR15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","volume":"348","author":"RS Sandler","year":"2003","unstructured":"Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883\u201390.","journal-title":"N Engl J Med"},{"key":"3757_CR16","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1136\/gutjnl-2013-305827","volume":"63","author":"H Ishikawa","year":"2014","unstructured":"Ishikawa H, Mutoh M, Suzuki S, Tokudome S, Saida Y, Abe T, et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut. 2014;63:1755\u20139.","journal-title":"Gut"},{"key":"3757_CR17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/gutjnl-2011-300113","volume":"61","author":"R Benamouzig","year":"2012","unstructured":"Benamouzig R, Uzzan B, Deyra J, Martin A, Girard B, Little J, et al. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut. 2012;61:255\u201361.","journal-title":"Gut"},{"key":"3757_CR18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","volume":"164","author":"K Bibbins-Domingo","year":"2016","unstructured":"Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement aspirin use for the primary prevention of CVD and CRC. Ann Intern Med. 2016;164:836\u201345.","journal-title":"Ann Intern Med"},{"key":"3757_CR19","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1001\/jama.297.18.2018","volume":"297","author":"CL Campbell","year":"2007","unstructured":"Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297:2018\u201324.","journal-title":"JAMA"},{"key":"3757_CR20","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.","journal-title":"BMJ"},{"key":"3757_CR21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61:64\u201375.","journal-title":"J Clin Epidemiol"},{"key":"3757_CR22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ije\/dyn188","volume":"38","author":"J Brok","year":"2009","unstructured":"Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive\u2014trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol. 2009;38:287\u201398.","journal-title":"Int J Epidemiol"},{"key":"3757_CR23","first-page":"188","volume":"17","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhang F-C, Wang Y-J. The efficacy and safety of non-steroidal anti-inflammatory drugs in preventing the recurrence of colorectal adenoma: a meta-analysis and systematic review of randomized trials. Colorectal Dis. Off. J. Assoc. Coloproctology G. B. Irel. 2015;17:188\u201396.","journal-title":"Colorectal Dis. Off. J. Assoc. Coloproctology G. B. Irel"},{"key":"3757_CR24","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/ije\/dym200","volume":"36","author":"E Flo\u00dfmann","year":"2007","unstructured":"Flo\u00dfmann E, Rothwell PM. Commentary: aspirin and colorectal cancer\u2014an epidemiological success story. Int J Epidemiol. 2007;36:962\u20135.","journal-title":"Int J Epidemiol"},{"key":"3757_CR25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jnci\/djn484","volume":"101","author":"MV Grau","year":"2009","unstructured":"Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, et al. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst. 2009;101:267\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"3757_CR26","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/ajg.2011.116","volume":"106","author":"N Arber","year":"2011","unstructured":"Arber N, Spicak J, R\u00e1cz I, Zavoral M, Breazna A, Gerletti P, et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol. 2011;106:1135\u201346.","journal-title":"Am J Gastroenterol"},{"key":"3757_CR27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1940-6207.CAPR-08-0206","volume":"2","author":"MM Bertagnolli","year":"2009","unstructured":"Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, et al. Five-year efficacy and safety analysis of the adenoma prevention with Celecoxib trial. Cancer Prev Res Phila Pa. 2009;2:310\u201321.","journal-title":"Cancer Prev Res Phila Pa"},{"key":"3757_CR28","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1053\/j.gastro.2006.08.079","volume":"131","author":"JA Baron","year":"2006","unstructured":"Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674\u201382.","journal-title":"Gastroenterology"},{"key":"3757_CR29","unstructured":"Veettil SK, Chaiyakunapruk N, Saokaew S, Ghee LK, Mooi CS. Comparative effectiveness of chemopreventive interventions for colorectal cancer: protocol for a systematic review and network meta-analysis. PROSPERO 2015; CRD42015025849. [Internet]. 2015. Available from: \nhttp:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42015025849"},{"key":"3757_CR30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.21037\/jgo.2016.04.02","volume":"7","author":"SK Veettil","year":"2016","unstructured":"Veettil SK, Saokaew S, Lim KG, Ching SM, Phisalprapa P, Chaiyakunapruk N. Comparative effectiveness of chemopreventive interventions for colorectal cancer: protocol for a systematic review and network meta-analysis of randomised controlled trials. J. Gastrointest Oncol. 2016;7:595\u2013602.","journal-title":"Gastrointest Oncol"},{"key":"3757_CR31","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].The Cochrane Collaboration. [Internet]. 2011. Available from: \nhttp:\/\/handbook.cochrane.org\n\n\/."},{"key":"3757_CR32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139. W64","journal-title":"Ann Intern Med"},{"key":"3757_CR33","first-page":"343","volume":"d5928","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;d5928:343.","journal-title":"BMJ"},{"key":"3757_CR34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"3757_CR35","unstructured":"Thorlund K, Engstr\u00f8m J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. 2011. p. 1\u2013115. [Internet]. Available from: from \nwww.ctu.dk\/tsa"},{"key":"3757_CR36","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"3757_CR37","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa061652","volume":"355","author":"N Arber","year":"2006","unstructured":"Arber N, Eagle CJ, Spicak J, R\u00e1cz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal Adenomatous polyps. N Engl J Med. 2006;355:885\u201395.","journal-title":"N Engl J Med"},{"key":"3757_CR38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","volume":"355","author":"MM Bertagnolli","year":"2006","unstructured":"Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873\u201384.","journal-title":"N Engl J Med"},{"key":"3757_CR39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1053\/j.gastro.2015.09.010","volume":"150","author":"H-C Pommergaard","year":"2016","unstructured":"Pommergaard H-C, Burcharth J, Rosenberg J, Raskov H. Aspirin, Calcitriol, and calcium do not prevent adenoma recurrence in a randomized controlled trial. Gastroenterology. 2016;150:114\u201322.","journal-title":"Gastroenterology"},{"issue":"89","key":"3757_CR40","first-page":"2011","volume":"13","author":"ZY Li","year":"2011","unstructured":"Li ZY, Gu JL, Zeng Z, Shi W. Clinical study of aspirin in the prevention of recurrence of colorectal adenoma in the elderly. Chinese J Med Guide. 2011;13(89):2011.","journal-title":"Chinese J Med Guide"},{"key":"3757_CR41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1940-6207.CAPR-08-0042","volume":"1","author":"FL Meyskens","year":"2008","unstructured":"Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev. Res. Phila. Pa. 2008;1:32\u20138.","journal-title":"Cancer Prev. Res. Phila. Pa"},{"key":"3757_CR42","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0016-5085(95)90206-6","volume":"108","author":"J Ladenheim","year":"1995","unstructured":"Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology. 1995;108:1083\u20137.","journal-title":"Gastroenterology"},{"key":"3757_CR43","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-10-2395","volume":"17","author":"T Takayama","year":"2011","unstructured":"Takayama T, Nagashima H, Maeda M, Nojiri S, Hirayama M, Nakano Y, et al. Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:3803\u201311.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3757_CR44","first-page":"343","volume":"d4002","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;d4002:343.","journal-title":"BMJ"},{"key":"3757_CR45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00228-003-0579-1","volume":"59","author":"J Gomez Cerezo","year":"2003","unstructured":"Gomez Cerezo J, Lubomirov Hristov R, Carcas Sansu\u00e1n AJ, V\u00e1zquez Rodr\u00edguez JJ. Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits. Eur J Clin Pharmacol. 2003;59:169\u201375.","journal-title":"Eur J Clin Pharmacol"},{"key":"3757_CR46","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","volume":"364","author":"P J\u00fcni","year":"2004","unstructured":"J\u00fcni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet Lond Engl. 2004;364:2021\u20139.","journal-title":"Lancet Lond Engl"},{"key":"3757_CR47","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","volume":"286","author":"D Mukherjee","year":"2001","unstructured":"Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954\u20139.","journal-title":"JAMA"},{"key":"3757_CR48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jclinepi.2008.09.013","volume":"62","author":"GF Borm","year":"2009","unstructured":"Borm GF, Lemmers O, Fransen J, Donders R. The evidence provided by a single trial is less reliable than its statistical analysis suggests. J Clin Epidemiol. 2009;62:711\u2013715.e1.","journal-title":"J Clin Epidemiol"},{"key":"3757_CR49","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/art.11192","volume":"49","author":"JJ Ofman","year":"2003","unstructured":"Ofman JJ, Maclean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2003;49:508\u201318.","journal-title":"Arthritis Rheum"},{"key":"3757_CR50","first-page":"804","volume":"29","author":"JJ Ofman","year":"2002","unstructured":"Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol. 2002;29:804\u201312.","journal-title":"J Rheumatol"},{"key":"3757_CR51","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1258\/jrsm.99.3.132","volume":"99","author":"B Caldwell","year":"2006","unstructured":"Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99:132\u201340.","journal-title":"J R Soc Med"},{"key":"3757_CR52","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.296.13.jrv60015","volume":"296","author":"J Zhang","year":"2006","unstructured":"Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296:1619\u201332.","journal-title":"JAMA"},{"key":"3757_CR53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","volume":"295","author":"JS Berger","year":"2006","unstructured":"Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306\u201313.","journal-title":"JAMA"},{"key":"3757_CR54","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/archinte.163.17.2006","volume":"163","author":"RS Eidelman","year":"2003","unstructured":"Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163:2006\u201310.","journal-title":"Arch Intern Med"},{"key":"3757_CR55","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Group BMJP","year":"2002","unstructured":"Group BMJP. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71\u201386.","journal-title":"BMJ"},{"key":"3757_CR56","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/bmj.312.7046.1563","volume":"312","author":"D Henry","year":"1996","unstructured":"Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312:1563\u20136.","journal-title":"BMJ"},{"key":"3757_CR57","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.amjcard.2005.01.049","volume":"95","author":"VL Serebruany","year":"2005","unstructured":"Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95:1218\u201322.","journal-title":"Am J Cardiol"},{"key":"3757_CR58","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(07)60747-8","volume":"369","author":"E Flossmann","year":"2007","unstructured":"Flossmann E, Rothwell PM, British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet Lond Engl. 2007;369:1603\u201313.","journal-title":"Lancet Lond Engl"},{"key":"3757_CR59","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","volume":"376","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet Lond. Engl. 2010;376:1741\u201350.","journal-title":"Lancet Lond. Engl"},{"key":"3757_CR60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","volume":"159","author":"NR Cook","year":"2013","unstructured":"Cook NR, Lee I-M, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77\u201385.","journal-title":"Ann Intern Med"},{"key":"3757_CR61","doi-asserted-by":"crossref","unstructured":"Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol. 1996;52:237\u201345.","DOI":"10.1016\/0006-2952(96)00181-5"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T06:51:56Z","timestamp":1510642316000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3757-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3757"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3757-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]},"article-number":"763"}}